Barclays PLC Boosts Stake in Enfusion, Inc. (NYSE:ENFN)

Barclays PLC lifted its position in shares of Enfusion, Inc. (NYSE:ENFN) by 251.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,039 shares of the company’s stock after acquiring an additional 61,554 shares during the quarter. Barclays PLC owned 0.07% of Enfusion worth $817,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ENFN. Arizona State Retirement System purchased a new stake in shares of Enfusion during the 2nd quarter worth about $86,000. Harbor Capital Advisors Inc. lifted its stake in Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares in the last quarter. Belvedere Trading LLC purchased a new position in Enfusion in the 3rd quarter valued at about $114,000. Paloma Partners Management Co purchased a new position in Enfusion in the 3rd quarter valued at about $157,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after buying an additional 4,239 shares in the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Enfusion

In other news, CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the sale, the chief executive officer now owns 526,702 shares in the company, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Bradley Herring sold 24,443 shares of Enfusion stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $10.61, for a total transaction of $259,340.23. Following the completion of the sale, the chief financial officer now owns 270,503 shares of the company’s stock, valued at $2,870,036.83. This trade represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,041 shares of company stock worth $597,367 in the last 90 days. Insiders own 36.44% of the company’s stock.

Enfusion Trading Up 0.9 %

ENFN stock opened at $10.91 on Thursday. The company has a market cap of $1.40 billion, a price-to-earnings ratio of 272.82, a PEG ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a 12 month low of $7.52 and a 12 month high of $11.38. The firm has a 50-day moving average of $10.22 and a two-hundred day moving average of $9.25.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ENFN shares. Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research note on Monday. Finally, Piper Sandler raised their price target on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.25.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.